Named-Patient Medicine Supply Recovery Leader

The mandate

The patient-supply vice president resigned after several authorised medicine requests missed dosing windows even though finished stock was available. Medical approval, named-patient permission, country label, patient-specific pack, batch and expiry reservation, import documentation and treatment-centre readiness moved through separate trackers. Teams protected doses before permits were likely, while other patients waited behind stock they could not legally or practically receive. The company must stabilise 310 individual supply paths without turning compassionate access into a launch programme.

The leader will start in Dublin within three weeks for fourteen months, spanning two production campaigns and permanent recruitment. The first 21 days will reconcile every active patient and stop reservations lacking a credible permission-to-dose path. Country cohorts will move onto one weekly control by month three; an expiry compression and treatment-reschedule exercise follows in month eight. Six weeks of patient-level handover are reserved after the successor starts.

Completion requires each patient supply path to join authorised request, country permission, prescription or order, product and batch, pack and label, expiry, depot, import document, courier, centre appointment, receipt and dose confirmation without exposing patient identity beyond need. Twelve consecutive weeks must show no preventable missed dose from supply sequencing. The successor receives open permissions, reserved batches, at-risk expiries, clinical holds, replacement decisions and the next two campaign calendars.

The interim may release or cancel internal patient reservations, prioritise approved pack and courier capacity, redirect eligible batches, approve expedited supply up to EUR 4 million and require country escalation. Medical retains patient eligibility; Regulatory owns access permission and authority communication; Quality owns batch disposition; clinicians own dosing; Privacy owns personal-data use; the executive committee approves programme closure, pricing, market launch or permanent supplier change.

Clinical development, regulatory strategy, commercial launch sequencing, physician engagement, medical eligibility, pricing, reimbursement and long-term manufacturing expansion are outside scope. The leader cannot promise treatment before each authorised owner has acted or use a patient narrative to bypass batch, permission or privacy control. This seat converts already authorised intent into executable individual supply and a transparent exception path.

Why this seat is open

The resignation followed repeated cases where every function had completed its task but the patient still could not receive medicine on time. Senior leaders were escalating individual stories without a comparable end-to-end population. A temporary executive is needed through two campaigns while the company appoints a permanent leader experienced in patient-specific rather than conventional market inventory.

What you will own

• Reconcile 310 patient paths across request, permission, order, batch, pack, expiry, depot, import, centre and dosing status.
• Cancel unsupported reservations and sequence eligible inventory through patient consequence, permission confidence and remaining dose window.
• Establish weekly patient-supply control that protects coded identity while exposing stalled owners, clocks and next decisions.
• Align packaging and labelling campaigns to country cohorts without creating unusable patient packs or stranded short-dated stock.
• Govern reschedule, damaged shipment, temperature event, permit delay and clinical-hold exceptions through authorised disposition.
• Exercise simultaneous expiry compression and treatment postponement across representative countries and constrained batches.
• Induct the successor through live patient cases, reserved stock, open permissions and the next two production campaigns.

Candidate qualifications

• Held global named-patient, early-access or highly individualised medicine supply authority across regulated international markets.
• Has reallocated a patient-reserved dose when permission, pack, expiry or treatment readiness made the original plan impossible.
• Understands medical request, country authorisation, patient pack, batch release, import, courier and dosing windows operationally.
• Can command supply while preserving clinician, Medical, Regulatory, Quality, Privacy and authority decision rights.
• Has managed coded patient-level control across dozens of countries without turning sensitive identity into general logistics data.
• Completed permanent handover only after individual supply paths survived production, permission and treatment-schedule disruption.

Non-negotiables

• Can start in Dublin within three weeks and sustain approximately 50% country, depot and treatment-centre travel.
• Brings direct named-patient medicine operations; conventional product launch or wholesaler planning alone is insufficient.
• Accepts Medical, Regulatory, Quality, clinician, Privacy, authority and executive-committee boundaries.
• Will disclose interests involving treatment centres, access vendors, couriers, depots, pack sites and patient organisations.

1. 49 words maximum. Describe a patient-reserved dose you reassigned because the original permission-to-dose path failed.
2. 49 words maximum. Confirm your Dublin start date and the largest named-patient population you directly controlled.
3. 49 words maximum. Which identifier should supply teams see when a patient's privacy boundary must remain intact?